Trial intelligence / Profile preview

Nitric Oxide in Pediatric Cardiopulmonary Bypass

NCT05101746Phase 3Enrolling by invitation

Sponsor
Vanderbilt University Medical Center
Start
Apr 2022
Primary completion
Sep 2026
Modality
DNA Intercalators/Alkylators, Inhalation Devices
Countries
1
01

Overview

A Phase 3 trial of nitric oxide in congenital heart disease (CHD), sponsored by Vanderbilt University Medical Center. Started Apr 2022; status: enrolling by invitation.

02

Drugs

nitric oxide
03

Conditions

congenital heart disease (CHD)

Beyond the preview

Go deeper on NCT05101746.

Study design, results and competitive context are available in the Gosset platform where reported.

Study design & results

Available in the Gosset platform where reported.

Competitive context

Available in the Gosset platform where reported.

Bring the full picture into focus.

See how Gosset can support your research on NCT05101746.

Gosset Free

Get started with Gosset.

Enter your corporate email.

Work email preferred.

Book a call